THE SHORT VERSION
- Wegovy’s familiar maintenance dose is 2.4mg weekly, but the MHRA has approved use up to a maximum of 7.2mg weekly for adult patients with obesity where clinically appropriate and prescribed. The 7.2mg dose should only be used exactly as directed by a prescriber.
This page explains UK regulatory updates and evidence context. It does not tell you whether a higher dose is right for you — only your prescriber can decide after reviewing your history, response and monitoring plan.
MHRA approvals
In January 2026 the MHRA announced approval of Wegovy up to 7.2mg weekly for adult patients with obesity. See MHRA approval of Wegovy up to 7.2mg.
In April 2026 the MHRA announced approval of a single-dose 7.2mg Wegovy pen for adult patients with obesity. See MHRA approval of the single-dose 7.2mg Wegovy pen.
STEP UP trial (careful framing)
Trial averages are not guarantees for any individual. Outcomes depend on adherence, lifestyle support, starting weight, dose reached and medical history.
7.2mg is not for everyone
- Do not imply all Wegovy patients should move to 7.2mg.
- Do not use GLP-1 medicines for cosmetic weight loss.
- Do not self-escalate dose or combine injections unless your prescriber has instructed you.
- Follow your prescriber, pharmacist or nurse for titration, monitoring and product information.
Sources you can check
- MHRA approval of Wegovy up to 7.2mg
- MHRA approval of the single-dose 7.2mg Wegovy pen
- STEP UP trial (The Lancet Diabetes & Endocrinology, 2025)
- NICE TA875 on semaglutide (Wegovy)
- MHRA GLP-1 medicines safety guidance
- MHRA Yellow Card scheme
- Wegovy 7.2mg Summary of Product Characteristics (eMC)
Editorial presentation updated 24 October 2026. This is general information, not individual medical advice or a claim of independent clinical review. Read the linked source and the leaflet supplied with your medicine for the full context. Suggest a correction.